Goldline Pharmaceutical IPO — Broker Reviews

The IPO is fully priced and shows higher margins compared to peers, which raises concerns. The business is dependent on third-party manufacturing. Suitable only for risk-seeking investors with a medium-term view.

Strong GMP trend indicates potential listing gains, but fundamentals rely heavily on outsourcing and small equity base may lead to volatility.

High subscription in retail segment and strong GMP suggest listing interest, but long-term sustainability depends on execution and margin stability.